Study on BI-1808 and Pembrolizumab for Patients with Advanced Solid Tumors

2 1 1 1

What is this study about?

This clinical trial is focused on studying treatments for advanced solid tumors, which are types of cancer that have spread beyond their original location. The study involves two medications: BI-1808 and pembrolizumab. BI-1808 is a new treatment being tested, and it is a type of medication known as a monoclonal antibody, which is designed to target specific proteins in the body. Pembrolizumab, also known by its brand name KEYTRUDA, is an existing cancer treatment that helps the immune system fight cancer cells.

The purpose of the study is to evaluate the safety and tolerability of BI-1808 when used alone and in combination with pembrolizumab. Participants will receive these treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will be conducted in phases, starting with testing BI-1808 by itself and then in combination with pembrolizumab. Researchers aim to find the most suitable dose that can be safely given to patients.

Throughout the study, participants will be monitored for any side effects or adverse reactions to the treatments. The study will also look at how the body processes BI-1808 and how it interacts with the immune system. This research is important for understanding how these treatments can be used to help people with advanced cancers and to determine the best way to use them in future treatments.

1 initial assessment

Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes reviewing medical history and current health status.

A biopsy may be required to obtain a sample of the tumor tissue, unless a previous sample is available and meets the study criteria.

2 phase 1, part a: single agent treatment

The first phase involves receiving BI-1808 as a single agent. This is administered through an intravenous (IV) infusion.

The dosage of BI-1808 is gradually increased to assess safety and tolerability. Monitoring for any adverse effects is conducted throughout this phase.

3 phase 1, part b: combination treatment

In this phase, BI-1808 is combined with pembrolizumab (also known as KEYTRUDA). Both are administered via IV infusion.

The combination aims to evaluate the safety and identify any dose-limiting toxicities. The goal is to determine the maximum tolerated dose.

4 phase 2a: recommended dose selection

Based on the findings from Phase 1, a recommended dose for Phase 2 is selected.

Participants continue to receive the treatment at this dose to further assess its effects on advanced malignancies.

5 ongoing monitoring and follow-up

Throughout the trial, regular monitoring of health status and any side effects is conducted.

Follow-up visits are scheduled to ensure the safety and effectiveness of the treatment.

Who Can Join the Study?

The patient must be willing and able to provide written permission to participate in the trial.
The patient must be at least 18 years old on the day they sign the permission form.
The patient must have a confirmed diagnosis of an advanced malignancy, which means a type of cancer that has spread or is not easily treatable.
The patient must have already received standard treatment for their condition, or be unable to tolerate it, refuse it, or not be eligible for it.
The patient must have at least one measurable area of disease, as defined by a specific set of guidelines called RECIST v 1.1.
The patient must be willing to safely undergo tissue biopsies, which are small samples taken from the affected area, if needed. If the doctor thinks it is not safe or possible, the biopsy is not required. A previous sample from a standard care biopsy can be used if it was taken after the last treatment and before joining the study.
The patient must have a life expectancy of at least 12 weeks.
The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, which is a scale used to assess how well a patient can perform daily activities.
The patient must have adequate organ function, which will be confirmed by lab tests.

Who Cannot Join the Study?

Patients who do not have advanced solid tumors cannot participate. Advanced solid tumors are a type of cancer that has spread and formed solid masses in the body.
Patients who are not within the specified age range cannot participate. The age range includes adults and older adults.
Patients who are not able to receive an intravenous (IV) infusion cannot participate. An IV infusion is a way to deliver medicine directly into the bloodstream through a vein.
Patients who are not able to tolerate the study medication or its combination with pembrolizumab cannot participate. Pembrolizumab is a medication used to help the immune system fight cancer.
Patients who are part of a vulnerable population, such as those with certain health conditions or disabilities, may not be eligible to participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name	City	Country
Central Hospital Of Northern Pest Military Hospital	Budapest	Hungary
Hospital General Universitario Gregorio Maranon	Madrid	Spain
Hospital Universitario 12 De Octubre	Madrid	Spain
Pharmaceutical Research Associates Magyarorszag	Budapest	Hungary
Lund University Hospital	Lund	Sweden
Karolinska University Hospital	Solna	Sweden
Hospital Universitario Fundacion Jimenez Diaz	Madrid	Spain
Rigshospitalet	Copenhagen	Denmark
Queen Silvia Childrens Hospital – Sahlgrenska University Hospital – Vaestra Goetalandsregionen	Gothenburg	Sweden
Isvbbpoe Ctsunv Dlwsjxvrofolfsdjm	L'hospitalet De Llobregat	Spain
Hsvvgp Hsgazvoh	Herlev	Denmark

Trial status

Country	Status	Recruitment Start
Denmark	Recruiting	01.12.2020
Hungary	Recruiting	01.12.2020
Spain	Recruiting	01.12.2020
Sweden	Recruiting	01.12.2020

Trial locations

Investigated drugs:

BI-1808 is a monoclonal antibody designed to target and block the activity of a specific protein known as Tumor Necrosis Factor Receptor 2 (TNFR2). This protein is involved in the growth and survival of cancer cells. By inhibiting TNFR2, BI-1808 aims to slow down or stop the progression of advanced cancers. In this trial, BI-1808 is being tested both as a standalone treatment and in combination with another medication to evaluate its safety and effectiveness.

Pembrolizumab is a type of cancer treatment known as an immune checkpoint inhibitor. It works by helping the immune system recognize and attack cancer cells more effectively. Pembrolizumab blocks a specific protein on the surface of immune cells, which can enhance the body’s natural defense against cancer. In this trial, pembrolizumab is used in combination with BI-1808 to assess whether the combination can improve treatment outcomes for patients with advanced cancers.

Advanced Solid Tumors – These are a group of cancers that originate in solid organs or tissues, such as the breast, lung, or colon, and have progressed to an advanced stage. At this stage, the tumors have typically spread beyond their original location to other parts of the body, making them more challenging to treat. The progression of advanced solid tumors often involves the growth of the primary tumor and the development of metastases, which are secondary cancerous growths. As the disease advances, it can affect the function of the organs involved and may lead to various symptoms depending on the location and size of the tumors. The behavior and progression of these tumors can vary widely depending on the type of cancer and individual patient factors.

Trial ID:

2023-509847-29-00

Protocol code:

19-BI-1808-01

NCT ID:

NCT04752826

Trial Phase:

Phase I and Phase II (Integrated) – First administration to humans

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on BI-1808 and Pembrolizumab for Patients with Advanced Solid Tumors

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?